Dicerna Pharmaceuticals Inc (DRNA) Peer Comparison

$38.22

$0.00 (0.00%)

As on 29-Dec-2021EDT

Market cap

$2,978 Mln

Revenue (TTM)

$193 Mln

P/E Ratio

--

P/B Ratio

27.7

Div. Yield

0 %

Edit

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Market cap ($ Mln)	2,978	2,928	2,262	2,152	1,111
Revenue ($ Mln)	193	450	120	549	4
Net Profit ($ Mln)	-124.44	-188.21	-57.50	17.88	-340.16
Net Margin (%)	-65.13	-41.86	-144.33	3.26	-540.52
RoE (%)	-106.33	-28.46	-9.86	1.43	501.41
Price to Earnings	--	--	--	123.80	--
Price-To-Book	27.66	4.96	4.15	1.71	2.10

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Operating Revenue	192.85	48.96	32.16	227.98	0.37
Cost of Revenue	0.00	239.45	81.50	188.52	0.85
Gross Profit	164.31	-190.49	-49.34	39.46	0.37
Operating Expenses	314.12	111.31	107.56	236.13	30.09
Operating Profit (EBIT)	-121.27	-301.80	-74.87	-198.62	-29.72
Other Income	-1.79	--	--	--	--
Profit before Tax	-123.08	-268.91	-87.36	-110.88	-33.62
Provision for Tax	1.36	30.38	-9.42	4.83	-2.00
Profit after Tax (Net Income)	-124.44	-268.91	-77.94	-125.73	-31.62
Minority Interest	0.00	--	--	--	--
Consolidated Profit	-124.44	-268.91	-77.94	-125.73	-33.62

Liabilities ($ Mln)

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Shareholder's Funds	107.66	1,169.35	549.33	484.12	111.21
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	425.10	30.25	94.13	46.77	13.80
Current Liabilities	239.30	98.04	90.14	158.40	13.91
Total Liabilities	707.85	1,297.64	733.60	724.12	138.92

Assets ($ Mln)

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Non-Current Assets	183.06	81.60	597.05	193.38	5.92
Current Assets	589.00	1,216.04	136.55	530.74	133.00
Total Assets	707.85	1,297.64	733.60	724.12	138.92
Total Debt*	64.42	18.60	99.31	38.90	10.06
Net Current Assets	349.71	1,117.99	46.41	372.34	119.09

Cashflow ($ Mln)

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Cash From Operating Activities	175.11	-216.06	-56.37	-62.07	-30.59
Cash Flow from Investing Activities	-258.86	-554.83	-3.27	-125.44	-8.56
Cash from Financing Activities	59.42	1,132.44	137.04	296.43	111.67
Net Cash Inflow / Outflow	-24.33	--	--	--	--

Ratios

Profitability Ratios

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
ROCE (%)	-61.67	-35.75	-12.87	-29.78	-38.86
ROE (%)	-106.33	-36.74	-15.13	-32.57	-41.44
ROA (%)	-12.88	-32.54	-11.25	-21.14	-32.29
EBIT Margin (%)	-63.82	--	--	--	--
Net Margin (%)	-65.13	-549.26	-242.38	-55.15	-8,500.81
Cash Profit Margin (%)	0.00	--	--	--	--

Growth Ratios

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Revenue Growth (%)	47.86	2.77	0.92	0.11	-0.95
EBIT Growth (%)	-0.12	--	--	--	--
Net Profit Growth (%)	-7.43	-46.65	13.21	-18.59	-4.64
EPS Growth (%)	-1.54	-0.14	0.20	-4.46	0.27
Book Value Growth (%)	-32.65	--	--	--	--

Valuation Ratios

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Price / Earnings	-14.46	-440.53	-7.95	-36.83	-17.57
Price / Book Value	11.83	101.30	1.13	9.57	5.00
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-10.08	-394.71	-8.55	-22.22	-16.27
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Debt to Equity	0.00	0.02	0.18	0.08	0.09
Short term debt to equity ratio	0.05	0.00	0.07	0.01	0.00
Current Ratio	2.46	12.40	1.51	3.35	9.56
Quick Ratio	2.46	12.27	1.52	3.23	9.54
Interest Coverage	-5,593.64	-1,667.41	-4.94	-249.90	-450.27

Operating Efficiency Ratios

	Dicerna Pharmaceuticals Inc (DRNA)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Inventiva Sa (IVA)
Debtors to sales (%)	3.23	10.55	4.11	21.00	12.90
Asset Turnover	0.20	0.06	0.05	0.38	0.00
Receivable days	264.69	33.41	17.40	100.17	339.23
Inventory Days	--	14.60	-1.12	34.85	152.62
Payable days	--	65.06	85.23	53.84	3,111.53
Cash Conversion Cycle	--	-17.05	-68.95	81.18	-2,619.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly